Soonmee Cha

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5231393/publications.pdf

Version: 2024-02-01

72 papers	4,304 citations	218662 26 h-index	114455 63 g-index
73 all docs	73 docs citations	73 times ranked	6572 citing authors

#	Article	IF	Citations
1	Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. Radiology, 2009, 253, 486-496.	7.3	365
2	Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas. American Journal of Neuroradiology, 2018, 39, 1201-1207.	2.4	323
3	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncology, The, 2019, 20, 1011-1022.	10.7	315
4	Current Clinical Brain Tumor Imaging. Neurosurgery, 2017, 81, 397-415.	1.1	281
5	Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro-Oncology, 2012, 14, 942-954.	1.2	183
6	Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. American Journal of Neuroradiology, 2005, 26, 266-73.	2.4	178
7	PET/MRI: Where might it replace PET/CT?. Journal of Magnetic Resonance Imaging, 2017, 46, 1247-1262.	3.4	175
8	Magnetic Resonance of 2-Hydroxyglutarate in IDH1 -Mutated Low-Grade Gliomas. Science Translational Medicine, 2012, 4, 116ra5.	12.4	161
9	Modern Brain Tumor Imaging. Brain Tumor Research and Treatment, 2015, 3, 8.	1.0	157
10	Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. Journal of Neurosurgery, 2005, 103, 428-438.	1.6	155
11	Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro-Oncology, 2017, 19, now254.	1.2	155
12	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. Journal of Neuro-Oncology, 2012, 108, 491-498.	2.9	149
13	Glioblastoma Multiforme Regional Genetic and Cellular Expression Patterns: Influence on Anatomic and Physiologic MR Imaging. Radiology, 2010, 254, 564-576.	7.3	148
14	Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation. American Journal of Neuroradiology, 2017, 38, 795-800.	2.4	132
15	Neuroimaging in Neuro-Oncology. Neurotherapeutics, 2009, 6, 465-477.	4.4	130
16	Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Clinical Cancer Research, 2018, 24, 5850-5859.	7.0	118
17	Perfusion MR Imaging of Brain Tumors. Topics in Magnetic Resonance Imaging, 2004, 15, 279-289.	1.2	99
18	Perfusion MR imaging: basic principles and clinical applications. Magnetic Resonance Imaging Clinics of North America, 2003, 11, 403-413.	1.1	81

#	Article	IF	Citations
19	MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. American Journal of Roentgenology, 2018, 210, 621-628.	2.2	75
20	Highâ€grade neuroepithelial tumor with BCOR exon 15 internal tandem duplicationâ€"a comprehensive clinical, radiographic, pathologic, and genomic analysis. Brain Pathology, 2020, 30, 46-62.	4.1	69
21	Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications. Brain Tumor Research and Treatment, 2017, 5, 1.	1.0	67
22	Metastasis in Adult Brain Tumors. Neuroimaging Clinics of North America, 2016, 26, 601-620.	1.0	41
23	A fully automated artificial intelligence method for non-invasive, imaging-based identification of genetic alterations in glioblastomas. Scientific Reports, 2020, 10, 11852.	3.3	41
24	Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. American Journal of Roentgenology, 2015, 205, 1075-1085.	2.2	38
25	MRI Features May Predict Molecular Features of Glioblastoma in Isocitrate Dehydrogenase Wild-Type Lower-Grade Gliomas. American Journal of Neuroradiology, 2021, 42, 448-456.	2.4	34
26	The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma. Neuro-Oncology, 2016, 18, 87-95.	1.2	33
27	Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis. American Journal of Neuroradiology, 2019, 40, 1804-1810.	2.4	27
28	Machine Learning Decision Tree Models for Differentiation of Posterior Fossa Tumors Using Diffusion Histogram Analysis and Structural MRI Findings. Frontiers in Oncology, 2020, 10, 71.	2.8	26
29	Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight, 2018, 3, .	5.0	26
30	Update on brain tumor imaging. Current Neurology and Neuroscience Reports, 2005, 5, 169-177.	4.2	24
31	Association of early changes in¹H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen. Neuro-Oncology, 2017, 19, now159.	1.2	24
32	Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. Journal of Neuro-Oncology, 2016, 130, 171-179.	2.9	24
33	Disruption of Frontal Aslant Tract Is Not Associated with Long-Term Postoperative Language Deficits. World Neurosurgery, 2020, 133, 192-195.	1.3	23
34	Case-based review: pediatric medulloblastoma. Neuro-Oncology Practice, 2017, 4, 138-150.	1.6	22
35	Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.7	22
36	Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathologica, 2019, 138, 877-881.	7.7	21

#	Article	IF	Citations
37	Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes. Journal of Neuro-Oncology, 2017, 134, 213-219.	2.9	21
38	Differentiation of Cerebellar Hemisphere Tumors: Combining Apparent Diffusion Coefficient Histogram Analysis and Structural MRI Features. Journal of Neuroimaging, 2018, 28, 656-665.	2.0	20
39	Advanced Imaging Techniques for Newly Diagnosed and Recurrent Gliomas. Frontiers in Neuroscience, 2022, 16, 787755.	2.8	18
40	Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Reports in Radiology, 2015, 2015, 1-4.	0.3	16
41	Location of subventricular zone recurrence and its radiation dose predicts survival in patients with glioblastoma. Journal of Neuro-Oncology, 2018, 138, 549-556.	2.9	16
42	Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Translational Oncology, 2017, 10, 895-903.	3.7	15
43	Feasibility of Simulated Postcontrast MRI of Glioblastomas and Lower-Grade Gliomas by Using Three-dimensional Fully Convolutional Neural Networks. Radiology: Artificial Intelligence, 2021, 3, e200276.	5.8	15
44	Intrameningioma Metastasis of Breast Carcinoma. Rare Tumors, 2014, 6, 49-52.	0.6	14
45	Advanced MR Imaging Techniques in Daily Practice. Neuroimaging Clinics of North America, 2016, 26, 647-666.	1.0	14
46	The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. Academic Radiology, 2016, 23, 1073-1082.	2.5	14
47	Adult-onset central nervous system hemophagocytic lymphohistiocytosis: a case report. BMC Neurology, 2015, 15, 203.	1.8	13
48	Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. Journal of Neuro-Oncology, 2017, 132, 171-179.	2.9	13
49	From Shades of Gray to Microbiologic Imaging: A Historical Review of Brain Abscess Imaging:RSNA Centennial Article. Radiographics, 2015, 35, 1555-1562.	3.3	12
50	Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines, 2016, 4, 24.	3.2	12
51	Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions. Journal of the Neurological Sciences, 2017, 381, 83-87.	0.6	11
52	EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. Acta Neuropathologica, 2022, 143, 109-113.	7.7	11
53	Early detection of recurrent medulloblastoma: the critical role of diffusion-weighted imaging. Neuro-Oncology Practice, 2018, 5, 234-240.	1.6	10
54	Prospective genomically guided identification of â€œearly/evolvingâ€•and â€œundersampledâ€•IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro-Oncology, 2022, 24, 1749-1762.	1.2	10

#	Article	IF	Citations
55	CNS Tumors. Topics in Magnetic Resonance Imaging, 2006, 17, 63-68.	1.2	9
56	Surgical Management of Intracranial Neuroenteric Cysts: The UCSF Experience. Journal of Neurological Surgery, Part B: Skull Base, 2015, 76, 475-479.	0.8	9
57	Identification of magnetic resonance imaging features for the prediction of molecular profiles of newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2021, 154, 83-92.	2.9	8
58	Functional outcomes after resection of middle frontal gyrus diffuse gliomas. Journal of Neurosurgery, 2022, 137, 1-8.	1.6	8
59	Biologically aggressive regions within glioblastoma identified by spin-lock contrast T1 relaxation in the rotating frame (T1Ῡ) MRI. Radiology Case Reports, 2017, 12, 827-832.	0.6	6
60	Susceptibility-Weighted Imaging of Intravascular Lymphoma of the Central Nervous System. JAMA Neurology, 2022, 79, 86.	9.0	6
61	Machine Learning Tools for Image-Based Glioma Grading and the Quality of Their Reporting: Challenges and Opportunities. Cancers, 2022, 14, 2623.	3.7	6
62	Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas. Neuro-Oncology, 2020, 22, 1516-1526.	1.2	5
63	Pre- and Post-Treatment Imaging of Primary Central Nervous System Tumors in the Molecular and Genetic Era. Korean Journal of Radiology, 2021, 22, 1858-1874.	3.4	4
64	ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium. American Journal of Neuroradiology, 2022, 43, 455-461.	2.4	3
65	CNS angiitis as a brain tumor mimic with a branching vascular abnormality on T2* MRI. Neurology, 2015, 85, 1819-1820.	1.1	2
66	PET/MRI: Where might it replace PET/CT?. Journal of Magnetic Resonance Imaging, 2017, 46, spcone.	3.4	2
67	Tailoring Radiology Resident Education Using Aggregated Missed-Cases Data. Journal of the American College of Radiology, 2018, 15, 1013-1015.	1.8	2
68	Involvement of the Olfactory Apparatus by Gliomas. American Journal of Neuroradiology, 2020, 41, 712-717.	2.4	2
69	Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas. Scientific Reports, 2021, 11, 14377.	3.3	2
70	Maximizing the use of batch production of 18F-FDOPA for imaging of brain tumors to increase availability of hybrid PET/MR imaging in clinical setting. Neuro-Oncology Practice, 2021, 8, 91-97.	1.6	1
71	NIMG-43. APPLICATION OF AN ADVANCED DIFFUSION-WEIGHTED MRI TECHNIQUE TO CHARACTERIZE GLIOMA MICROSTRUCTURE AND RELATIONSHIP TO HISTOPATHOLOGY. Neuro-Oncology, 2016, 18, vi134-vi134.	1.2	0
72	Systemic and Craniospinal Rosai Dorfman Disease with Intraparenchymal, Intramedullary and Leptomeningeal Disease. International Journal of Hematology-Oncology and Stem Cell Research, 2021, 15, 260-264.	0.3	0